Kindred Biosciences, Inc. (KIN) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME, CA 94010 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 63,309 | 59,900 | 66,837 | 77,573 | 54,571 | 73,500 | |||
| Cash and cash equivalent | 12,911 | 11,620 | 16,614 | 26,898 | 13,960 | 15,986 | |||
| Short-term investments | 50,240 | 46,758 | 45,723 | 40,218 | 39,493 | 55,723 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 158 | 1,522 | 4,500 | 10,457 | 1,118 | 1,791 | |||
| Receivables | 12,715 | 624 | 739 | 263 | 244 | 923 | |||
| Inventory, net of allowances, customer advances and progress billings | 207 | 386 | 389 | 824 | 4,218 | ||||
| Inventory | 207 | 386 | 389 | 824 | 4,218 | ||||
| Other undisclosed current assets | 3,067 | 1,893 | (206) | (5,454) | 2,775 | 704 | |||
| Total current assets: | 79,091 | 62,624 | 67,756 | 72,771 | 58,414 | 79,345 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 3,225 | 3,428 | 3,634 | 3,082 | 2,833 | 3,001 | |||
| Property, plant and equipment | 27,451 | 28,204 | 28,593 | 29,569 | 30,292 | 29,777 | |||
| Long-term investments and receivables | 158 | 1,500 | 4,500 | 10,457 | 1,118 | 1,837 | |||
| Long-term investments | 158 | 1,500 | 4,500 | 10,457 | 1,118 | 1,837 | |||
| Other noncurrent assets | 54 | 58 | 56 | 63 | 64 | 64 | |||
| Total noncurrent assets: | 30,888 | 33,190 | 36,783 | 43,171 | 34,307 | 34,679 | |||
| TOTAL ASSETS: | 109,979 | 95,814 | 104,539 | 115,942 | 92,721 | 114,024 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 2,893 | 4,960 | 4,520 | 6,292 | 9,577 | 9,580 | |||
| Employee-related liabilities | 1,372 | 2,070 | 2,162 | 4,091 | 3,587 | 4,193 | |||
| Accounts payable | 353 | 145 | 347 | 639 | 2,837 | 1,256 | |||
| Accrued liabilities | 1,168 | 2,745 | 2,011 | 1,562 | 3,153 | 4,131 | |||
| Debt | 2,815 | 1,111 | 618 | 644 | |||||
| Other undisclosed current liabilities | 844 | 825 | 811 | 657 | |||||
| Total current liabilities: | 6,552 | 6,896 | 5,331 | 6,949 | 10,195 | 10,224 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 19,642 | 21,436 | 22,671 | 22,177 | 21,856 | 21,879 | |||
| Long-term debt, excluding current maturities | 16,926 | 18,502 | 19,524 | 19,436 | 19,350 | 19,265 | |||
| Operating lease, liability | 2,716 | 2,934 | 3,147 | 2,741 | 2,506 | 2,614 | |||
| Other undisclosed noncurrent liabilities | (2,716) | (2,934) | (3,147) | (2,741) | |||||
| Total noncurrent liabilities: | 19,642 | 18,502 | 22,671 | 22,177 | 21,856 | 21,879 | |||
| Total liabilities: | 26,194 | 28,332 | 28,002 | 29,126 | 32,051 | 32,103 | |||
| Equity | |||||||||
| Equity, attributable to parent | 83,785 | 67,482 | 76,537 | 86,816 | 60,670 | 81,921 | |||
| Common stock | 4 | 4 | 4 | 4 | 4 | 4 | |||
| Additional paid in capital | 338,374 | 312,321 | 310,466 | 308,542 | 306,482 | 304,963 | |||
| Accumulated other comprehensive income (loss) | 2 | 12 | 24 | 44 | 4 | 13 | |||
| Accumulated deficit | (254,595) | (244,855) | (233,957) | (221,774) | (245,820) | (223,059) | |||
| Total equity: | 83,785 | 67,482 | 76,537 | 86,816 | 60,670 | 81,921 | |||
| TOTAL LIABILITIES AND EQUITY: | 109,979 | 95,814 | 104,539 | 115,942 | 92,721 | 114,024 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 2,395 | 951 | 1,043 | 39,567 | 603 | 1,401 | ||
| Cost of revenue (Cost of Product and Service Sold) | (590) | (381) | (305) | (363) | (3,577) | (187) | ||
| Gross profit: | 1,805 | 570 | 738 | 39,204 | (2,974) | 1,214 | ||
| Operating expenses | (10,971) | (10,932) | (12,367) | (14,791) | (19,440) | (16,524) | ||
| Other undisclosed operating income (loss) | 24 | (188) | ||||||
| Operating income (loss): | (9,166) | (10,362) | (11,629) | 24,413 | (22,390) | (15,498) | ||
| Nonoperating expense | (574) | (536) | (554) | (367) | (371) | (236) | ||
| Investment income, nonoperating | (73) | (85) | 109 | (236) | ||||
| Income (loss) from continuing operations: | (9,740) | (10,898) | (12,183) | 24,046 | (22,761) | (15,734) | ||
| Income (loss) before gain (loss) on sale of properties: | (9,740) | (10,898) | (12,183) | 24,046 | (22,761) | (15,734) | ||
| Net income (loss) available to common stockholders, diluted: | (9,740) | (10,898) | (12,183) | 24,046 | (22,761) | (15,734) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (9,740) | (10,898) | (12,183) | 24,046 | (22,761) | (15,734) | ||
| Comprehensive income (loss): | (9,740) | (10,898) | (12,183) | 24,046 | (22,761) | (15,734) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (10) | (12) | (20) | 40 | (9) | (5) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (9,750) | (10,910) | (12,203) | 24,086 | (22,770) | (15,739) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.